Olfactory and gustatory dysfunctions in COVID-19 outpatients: A prospective cohort study
Infectious Diseases Now. 2021-08-01; 51(5): 440-444
DOI: 10.1016/j.idnow.2021.03.004
Lire sur PubMed
1. Infect Dis Now. 2021 Aug;51(5):440-444. doi: 10.1016/j.idnow.2021.03.004. Epub
2021 Mar 22.
Olfactory and gustatory dysfunctions in COVID-19 outpatients: A prospective
cohort study.
Cousyn L(1), Sellem B(2), Palich R(3), Bendetowicz D(4), Agher R(3), Delorme
C(5), Tubiana R(3), Valantin MA(3), Seang S(3), Schneider L(3), Fayçal A(2),
Dudoit Y(3), Abdi B(6), Ndoadoumgue A(7), Assoumou L(7), Katlama C(3);
COVIDOM-19 PSL group.
Author information:
(1)Department of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France;
Paris Brain Institute (Inserm, CNRS, Sorbonne Université), Paris, France.
Electronic address: .
(2)Department of Infectious Diseases, Pitié-Salpêtrière Hospital, AP-HP, Paris,
France.
(3)Department of Infectious Diseases, Pitié-Salpêtrière Hospital, AP-HP, Paris,
France; Inserm, Sorbonne Université, Institut Pierre-Louis d’épidémiologie et de
santé publique (IPLESP), Paris, France.
(4)Department of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France;
Paris Brain Institute (Inserm, CNRS, Sorbonne Université), Paris, France.
(5)Department of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
(6)Inserm, Sorbonne Université, Institut Pierre-Louis d’épidémiologie et de
santé publique (IPLESP), Paris, France; Department of Virology,
Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
(7)Inserm, Sorbonne Université, Institut Pierre-Louis d’épidémiologie et de
santé publique (IPLESP), Paris, France.
OBJECTIVES: To describe the characteristics, evolution and risk factors for
long-term persistence of olfactory and gustatory dysfunctions (OGD) in COVID-19
outpatients.
PATIENTS AND METHODS: We conducted a prospective study in SARS-CoV-2 infected
outpatients with OGD. Weekly phone interviews were set up starting from COVID-19
onset symptoms and over the course of 60 days, using standardized questionnaires
that included a detailed description of general symptoms and OGD. The primary
outcome was the proportion of patients with complete recovery of OGD at D30.
Rate and time to recovery of OGD, as well as risk factors for late recovery (>30
days), were evaluated using Cox regression models.
RESULTS: Ninety-eight outpatients were included. The median time to onset of OGD
after first COVID-19 symptoms was 2 days (IQR 0-4). The 30-day recovery rate
from OGD was 67.5% (95% CI 57.1-75.4) and the estimated median time of OGD
recovery was 20 days (95% CI 13-26). Risk factors for late recovery of OGD were
a complete loss of smell or taste at diagnosis (HR=0.26, 95% CI 0.12-0.56,
P=0.0005) and age over 40 years (HR=0.56, 95% CI 0.36-0.89, P=0.01).
CONCLUSIONS: COVID-19 patients with complete loss of smell or taste and over age
40 are more likely to develop persistent OGD and should rapidly receive
sensorial rehabilitation.
Copyright © 2021 Elsevier Masson SAS. All rights reserved.
DOI: 10.1016/j.idnow.2021.03.004
PMCID: PMC7983360
PMID: 33766735 [Indexed for MEDLINE]